Ann: Corporate Update, page-44

I appreciate your view on Fitbit attacking the same market and having more clout in the space.

I believe it’s a net positive though, it shows that CDX are obviously producing something of value and in the right ballpack. Whether we work with fitbit or not I don't think it matters. Ultimately the tech is becoming more validated and fitbit is far from the only player in the space. Any of the major players could by CDX for pocket change and be well ahead of Fitbit almost overnight, which bodes well for us.

Craig and Niall are PE/Venture capital guys so building out a saleable business would be second nature to them. And in my opinion when to exit, under what terms have already been discussed and the targets set. Eg $5 performance options being in place to me highlight a small breadcrumb of how they have laid early foundations with the future in mind.

It's still early days yet in the journey but backing up their biomarker portfolio behind the cardiac stuff is a solid strategy. As many of you are aware, science is uncovering more and more heart metrics including arterial stiffness are becoming diagnostic for many health conditions external to cardiovascular. As these grow the value of accurately measuring these biomarkers grow.

One thing we have above the rest will be the data gathered by clinicians, 30 or so years of it to build the algos and calibrate the devices. Perhaps something the Bayer’s of the world already know and hence why they are interested.

Finally, it's good to see some green, I topped up around here on the way down, well done to those who got the lows. I'm hoping to see the timeframes being hit a round production and release of the Pulse. We’ll likely see marketing continue to ramp up, I don't think the broader market will start giving CDX a genuine look when the capital situation has been put to bed. Fingers crossed shareholder meeting is called for this month as stated.

Cheers all for sharing their research, especially Qman!